For Immediate Release
Chicago, IL - December 15, 2011 - Zacks.com releases details on
a group of stocks that are currently members of the exclusive Zacks
#5 Rank List - Stocks to Sell Now. These stocks are currently rated
as a Zacks Rank #5 (Strong Sell):
Pegasystems Inc.
(
PEGA
) and
Rovi Corporation
(
ROVI
). Further, Zacks announced #4 Rankings (Sell) on two other widely
held stocks:
Masimo Corporation
(
MASI
) and
ShangPharma Corp
(
SHP
).
To see the full Zacks #5 Rank List -
Stocks to Sell
Now visit
:
http://at.zacks.com/?id=92
Since inception in 1988, the S&P 500 has outperformed the
Zacks #5 Rank List of Stocks to Sell Now by 80% annually (+2% vs.
+10%). While the rest of Wall Street continued to tout stocks
during the market declines of the last few years, Zacks told
investors which stocks to sell or avoid.
Here is a synopsis of why PEGA and ROVI have a Zacks Rank of #5
(Strong Sell) and should most likely be sold or avoided for the
next one to three months. Note that a #5 Strong Sell rating is
applied to 5% of all the stocks in the Zacks Rank universe:
Pegasystems Inc.
(
PEGA
) announced third-quarter profit of 13 cents per share on November
9 that missed analysts' expectations by 53.57%. The Zacks Consensus
Estimate for the current year slid to 43 cents per share from $1.02
per share in the last 60 days as next year's estimate dipped 50
cents per share to 85 cents per share in that time span.
Rovi Corporation
(
ROVI
) posted a third-quarter profit of 30 cents per share on November
8, which came in 16 cents wider than the average forecast. The
Zacks Consensus Estimate for the full year fell to $2.02 per share
from $2.08 per share over the past two months. For 2012, analysts
expect a profit of $2.16 per share, compared to last two month's
projection for a profit of $2.54 per share.
Here is a synopsis of why MASI and SHP have a Zacks Rank of 4
(Sell) and should also most likely be sold or avoided for the next
one to three months. Note that a #4 Sell rating is applied to 15%
of all the stocks ranked by Zacks;
Masimo Corporation
(
MASI
) third-quarter profit of 24 cents per share, posted on October 25,
lagged analysts' projections by 14.29%. Estimate for current year
slid 11 cents per share to $1.05 per share over two months as next
year's estimate dipped 21 cents per share to $1.21 per share in
that time span.
ShangPharma Corp
(
SHP
) reported a third-quarter profit of 14 cents per share on November
21 that fell 22.22% short of the Zacks Consensus Estimate. The
full-year average forecast is currently 65 cents per share,
compared with last month's projection of 72 cents per share. Next
year's forecast dropped to 79 cents per share from 86 cents per
share in the same period.
Truly taking advantage of the Zacks Rank requires the
understanding of how it works. The free special report;
"Zacks Rank Guide: Harnessing the Power of Earnings Estimate
Revisions" is available to provide this insightful background.
Download a free copy now to prosper in the years to come at
http://at.zacks.com/?id=93
About the Zacks Rank
Since 1988, the Zacks Rank has proven that "Earnings estimate
revisions are the most powerful force impacting stock prices."
Since inception in 1988, #1 Rank Stocks have generated an average
annual return of +28%. During the 2000-2002 bear market, Zacks #1
Rank stocks gained +43.8%, while the S&P 500 tumbled -37.6%.
Also note that the Zacks Rank system has just as many Strong Sell
recommendations (Rank #5) as Strong Buy recommendations (Rank #1).
Since 1988, Zacks Rank #5 stocks have significantly underperformed
the S&P 500 (2.8% versus +9.7%). Thus, the Zacks Rank system
allows investors to truly manage portfolio trading effectively.
Visit
http://www.zacks.com/performance
for information about the performance numbers displayed in this
press release.
Zacks "Profit from the Pros" e-mail newsletter offers continuous
coverage of Zacks Rank Buy stocks and highlights those stocks
poised to outperform the market. Subscribe to this free newsletter
today by visiting
http://at.zacks.com/?id=94
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc.,
which was formed in 1978 by Len Zacks. As a PhD from MIT Len knew
he could find patterns in stock market data that would lead to
superior investment results. Amongst his many accomplishments was
the formation of his proprietary stock picking system; the Zacks
Rank, which continues to outperform the market by nearly a 3 to 1
margin. The best way to unlock the profitable stock recommendations
and market insights of Zacks Investment Research is through our
free daily email newsletter; Profit from the Pros. In short,
it's your steady flow of Profitable ideas GUARANTEED to be worth
your time! Register for your free subscription to Profit from the
Pros at
http://at.zacks.com/?id=95
Follow us on Twitter:
http://twitter.com/zacksresearch
Join us on Facebook:
http://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with
affiliated entities (including a broker-dealer and an investment
adviser), which may engage in transactions involving the foregoing
securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future
results. Investors should always research companies and
securities before making any investments. Nothing herein should be
construed as an offer or solicitation to buy or sell any
security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
MASIMO CORP (
MASI
): Free Stock Analysis Report
PEGASYSTEMS INC (
PEGA
): Free Stock Analysis Report
ROVI CORP (
ROVI
): Free Stock Analysis Report
SHANGPHARMA-ADR (SHP): Free Stock Analysis
Report
Zacks Investment
Research